{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:53:22Z","timestamp":1790175202111,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jviromet.2026.115432","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:35:04Z","timestamp":1782052504000},"page":"115432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development"],"prefix":"10.1016","volume":"345","author":[{"given":"Taruna","family":"Ikrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wachyudi","family":"Muchsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-2110","authenticated-orcid":false,"given":"Alfi","family":"Sophian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2026.115432_bib1","unstructured":"World Health Organization. Influenza (Seasonal). WHO Fact Sheets. 2023. Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza\u3009-(seasonal)."},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918-1920 \"Spanish\" influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"10.1016\/j.jviromet.2026.115432_bib3","unstructured":"World Health Organization. COVID-19 Dashboard. 2024. Available from: \u3008https:\/\/covid19.who.int\u3009."},{"issue":"18","key":"10.1016\/j.jviromet.2026.115432_bib4","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1073\/pnas.0610941104","article-title":"Public health interventions and epidemic intensity during the 1918 influenza pandemic","volume":"104","author":"Hatchett","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"issue":"7798","key":"10.1016\/j.jviromet.2026.115432_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/mr.56.1.152-179.1992","article-title":"Evolution and ecology of influenza A viruses","volume":"56","author":"Webster","year":"1992","journal-title":"Microbiol. Rev."},{"issue":"8","key":"10.1016\/j.jviromet.2026.115432_bib8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib9","first-page":"69","article-title":"Efficacy of influenza vaccines in ferrets against a contemporary H5N1 highly pathogenic avian influenza virus","volume":"8","author":"Creager","year":"2023","journal-title":"NPJ Vaccin."},{"issue":"27","key":"10.1016\/j.jviromet.2026.115432_bib10","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1016\/j.vaccine.2018.05.057","article-title":"Economic burden of seasonal influenza in the United States","volume":"36","author":"Putri","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib11","article-title":"Severe acute respiratory illness coronavirus and rhinovirus illnesses in adults, United States, 2009-2010","volume":"2","author":"Prill","year":"2015","journal-title":"Open. Forum Infect. Dis."},{"issue":"3","key":"10.1016\/j.jviromet.2026.115432_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib13","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1038\/s41467-020-17687-3","article-title":"Origin and cross-species transmission of bat coronaviruses in China","volume":"11","author":"Latinne","year":"2020","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.jviromet.2026.115432_bib14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMp2002106","article-title":"Escaping Pandora's box\u2014another novel coronavirus","volume":"382","author":"Morens","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6044","key":"10.1016\/j.jviromet.2026.115432_bib15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"issue":"6100","key":"10.1016\/j.jviromet.2026.115432_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.1222908","article-title":"Highly conserved protective epitopes on influenza B viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jviromet.2026.115432_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00150-11","article-title":"Why do influenza virus subtypes die out? A hypothesis","volume":"2","author":"Palese","year":"2011","journal-title":"mBio"},{"issue":"22","key":"10.1016\/j.jviromet.2026.115432_bib18","first-page":"12973","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"88","author":"Krammer","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2026.115432_bib19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3389\/fcimb.2019.00344","article-title":"The quest for a truly universal influenza vaccine","volume":"9","author":"Jang","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"2","key":"10.1016\/j.jviromet.2026.115432_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold","year":"2015","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.jviromet.2026.115432_bib21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/vaccines3010105","article-title":"M2e-based universal influenza A vaccines","volume":"3","author":"Deng","year":"2015","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.jviromet.2026.115432_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"6519","key":"10.1016\/j.jviromet.2026.115432_bib24","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1126\/science.abe3354","article-title":"Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms","volume":"370","author":"Tortorici","year":"2020","journal-title":"Science"},{"issue":"6530","key":"10.1016\/j.jviromet.2026.115432_bib25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jviromet.2026.115432_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"6559","key":"10.1016\/j.jviromet.2026.115432_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"issue":"6511","key":"10.1016\/j.jviromet.2026.115432_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1126\/science.abc7424","article-title":"Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein","volume":"369","author":"Wec","year":"2020","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.jviromet.2026.115432_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00647-20","article-title":"The nucleocapsid protein of SARS-CoV-2: a target for vaccine development","volume":"94","author":"Dutta","year":"2020","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.jviromet.2026.115432_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.jviromet.2026.115432_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jviromet.2026.115432_bib32","unstructured":"Moderna Inc A Phase 3, Randomized, Observer-Blind, Active Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1010. ClinicalTrials.gov NCT05566639. 2023."},{"issue":"6622","key":"10.1016\/j.jviromet.2026.115432_bib33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.jviromet.2026.115432_bib34","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jviromet.2026.115432_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS. One"},{"issue":"7456","key":"10.1016\/j.jviromet.2026.115432_bib36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"6606","key":"10.1016\/j.jviromet.2026.115432_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models","volume":"377","author":"Cohen","year":"2022","journal-title":"Science"},{"issue":"7855","key":"10.1016\/j.jviromet.2026.115432_bib38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"issue":"6254","key":"10.1016\/j.jviromet.2026.115432_bib39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"issue":"6483","key":"10.1016\/j.jviromet.2026.115432_bib40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6510","key":"10.1016\/j.jviromet.2026.115432_bib41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.jviromet.2026.115432_bib42","first-page":"3383","article-title":"An antibody with a combination of unusual features is a major contributor to incompletely understood influenza immunity","volume":"28","author":"Andrews","year":"2019","journal-title":"Cell. Rep."},{"issue":"2","key":"10.1016\/j.jviromet.2026.115432_bib43","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.jviromet.2026.115432_bib44","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50-64 years of age","volume":"376","author":"Dunkle","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat. Med."},{"issue":"7874","key":"10.1016\/j.jviromet.2026.115432_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41586-021-03807-6","article-title":"SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape","volume":"597","author":"Starr","year":"2021","journal-title":"Nature"},{"issue":"632","key":"10.1016\/j.jviromet.2026.115432_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi5735","article-title":"A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates","volume":"14","author":"Joyce","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"6558","key":"10.1016\/j.jviromet.2026.115432_bib48","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1126\/science.abi4506","article-title":"Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice","volume":"373","author":"Martinez","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jviromet.2026.115432_bib49","unstructured":"Coalition for Epidemic Preparedness Innovations (CEPI). CEPI's Investment in Universal Flu Vaccine Development. 2023. Available from: \u3008https:\/\/cepi.net\u3009."},{"issue":"8106","key":"10.1016\/j.jviromet.2026.115432_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(79)90468-9","article-title":"Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital","volume":"1","author":"Hoskins","year":"1979","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jviromet.2026.115432_bib51","first-page":"572","article-title":"On the doctrine of original antigenic sin","volume":"104","author":"Francis","year":"1960","journal-title":"Proc. Am. Philos. Soc."},{"issue":"75","key":"10.1016\/j.jviromet.2026.115432_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq2427","article-title":"Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes","volume":"7","author":"Quandt","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jviromet.2026.115432_bib53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a universal influenza virus vaccine possible?","volume":"71","author":"Nachbagauer","year":"2020","journal-title":"Annu. Rev. Med."},{"issue":"21","key":"10.1016\/j.jviromet.2026.115432_bib54","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.1994.03520210045030","article-title":"The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial","volume":"272","author":"Govaert","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jviromet.2026.115432_bib55","doi-asserted-by":"crossref","first-page":"a028845","DOI":"10.1101\/cshperspect.a028845","article-title":"Is it possible to develop a \"universal\" influenza virus vaccine? Potential target antigens and critical aspects for a universal influenza vaccine","volume":"10","author":"Krammer","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6576","key":"10.1016\/j.jviromet.2026.115432_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jviromet.2026.115432_bib57","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin. Vaccin. Immunol."},{"issue":"7830","key":"10.1016\/j.jviromet.2026.115432_bib58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"10278","key":"10.1016\/j.jviromet.2026.115432_bib59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jviromet.2026.115432_bib60","doi-asserted-by":"crossref","first-page":"vex012","DOI":"10.1093\/ve\/vex012","article-title":"Global patterns in coronavirus diversity","volume":"3","author":"Anthony","year":"2017","journal-title":"Virus Evol."},{"issue":"5","key":"10.1016\/j.jviromet.2026.115432_bib61","article-title":"The potential role of serology in combating SARS-CoV-2","volume":"14","author":"Kearns","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"7830","key":"10.1016\/j.jviromet.2026.115432_bib62","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"7490","key":"10.1016\/j.jviromet.2026.115432_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature13087","article-title":"A predictive fitness model for influenza","volume":"507","author":"Luksza","year":"2014","journal-title":"Nature"},{"issue":"9980","key":"10.1016\/j.jviromet.2026.115432_bib64","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(15)60858-3","article-title":"Global health security: the wider lessons from the west African Ebola virus disease epidemic","volume":"385","author":"Heymann","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2026.115432_bib65","series-title":"WHO Global Action Plan for Influenza Vaccines (GAP)","author":"World Health Organization","year":"2006"},{"key":"10.1016\/j.jviromet.2026.115432_bib66","unstructured":"G7 Health Ministers. 100 Days Mission \u2014 G7 Commitments on Pandemic Preparedness. 2021. Available from: \u3008https:\/\/www.g7uk.org\u3009."},{"issue":"10009","key":"10.1016\/j.jviromet.2026.115432_bib67","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/S0140-6736(15)00946-0","article-title":"Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola","volume":"386","author":"Moon","year":"2015","journal-title":"Lancet"},{"issue":"7873","key":"10.1016\/j.jviromet.2026.115432_bib68","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jviromet.2026.115432_bib69","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMp2118468","article-title":"Universal coronavirus vaccines\u2014an urgent need","volume":"386","author":"Morens","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jviromet.2026.115432_bib70","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines\u2014fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.jviromet.2026.115432_bib71","article-title":"A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques","volume":"2","author":"Hassan","year":"2021","journal-title":"Cell. Rep. Med."},{"issue":"5","key":"10.1016\/j.jviromet.2026.115432_bib72","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging pandemic diseases: how we got to COVID-19","volume":"182","author":"Morens","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jviromet.2026.115432_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.115019","article-title":"mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access","volume":"395","author":"Ikrar","year":"2026","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jviromet.2026.115432_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.70149","article-title":"Abinawanto. Global vaccine confidence at a crossroads: Immunisation coverage declines, misinformation, and the future of vaccine policy","volume":"36","author":"Sophian","year":"2026","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.jviromet.2026.115432_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128381","article-title":"Maternal immunization against group B Streptococcus: Immune correlates, microbiome trade-offs, and global implementation challenges","volume":"77","author":"Ikrar","year":"2026","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2026.115432_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128393","article-title":"Global implications of recent changes in U.S. vaccine policy: Ethical and trust challenges for immunization programs","volume":"77","author":"Sophian","year":"2026","journal-title":"Vaccine"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093426000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093426000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:31:03Z","timestamp":1784622663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093426000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":76,"alternative-id":["S0166093426000972"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2026.115432","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond strain-specific immunity: Conserved antigenic targets, emerging platforms, and translational challenges in universal influenza and pan-coronavirus vaccine development","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2026.115432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115432"}}